NCT01991301 is a Phase 1 clinical trial of carfilzumib in Graft-versus-host Disease, sponsored by Sheba Medical Center.

Who is sponsoring NCT01991301?

NCT01991301 is sponsored by Sheba Medical Center.

What drugs are being tested in NCT01991301?

Interventions in NCT01991301: carfilzumib.

What condition does NCT01991301 study?

NCT01991301 studies Graft-versus-host Disease.

Is NCT01991301 still recruiting?

NCT01991301 is currently status unknown. Last updated 1 December 2015.

Last reviewed 2015-12-01 · How we verify

NCT01991301

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Safety and Efficacy of Carfilzomib -a Novel Proteasome Inhibitor- for the Prevention of Acute Graft Versus Host Disease

Status unknown Phase 1 Last updated 1 December 2015

What this trial tests

Phase 1 trial testing carfilzumib in Graft-versus-host Disease in 30 participants. Status unknown.

Timeline

1 November 2014

Primary endpoint
1 November 2017

1 November 2017

Quick facts

Lead sponsor	Sheba Medical Center
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 November 2014
Primary completion	1 November 2017
Estimated completion	1 November 2017
Sites	1 location across Israel

Drugs / interventions tested

carfilzumib — full drug profile →

Conditions studied

Graft-versus-host Disease — all drugs for Graft-versus-host Disease →

Sponsor

Sheba Medical Center

Who can join

Adults 18 to 70, any sex, with Graft-versus-host Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

incidence of acute graft-versus host disease
Time frame: 3 months
We will evaluate the incidence of acute GVHD, grading and organ involvementBY STANDARD INTERNATIONAL CRITERIA.

Sponsor's own description

The aim of this study is to evaluate the safety and efficacy of Carfilzumib, which is a novel biological agent used in the treatment of multiple myeloma in preventing graft-versus-host disease, after stem cells transplantation from unrelated donors.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-<i>Versus</i>-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation.
Vandenhove B, Canti L, Schoemans H, Beguin Y, et al · · 2020 · cited 7× · PMID 33193397 · DOI 10.3389/fimmu.2020.583564
Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies.
Wang Y, Liu W, Huang X, Xiao Y. · · 2026 · PMID 42008224 · DOI 10.1007/s12015-026-11131-7
Carfilzomib combined with cyclosporine and methotrexate for the prevention of graft-versus-host disease after allogeneic stem-cell transplantation from unrelated donors.
Shimoni A, Shem-Tov N, Yerushalmi R, Danylesko I, et al · · 2021 · PMID 32873915 · DOI 10.1038/s41409-020-01044-5

Verify or expand the search:

Other recruiting trials for Graft-versus-host Disease

Currently open trials in the same condition.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT04014413 — Safety and Efficacy of Fecal Microbiota Transplantation · NA · recruiting

Other Sheba Medical Center trials

Trials by the same sponsor.

NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
NCT07523373 — Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch · NA · not yet recruiting
NCT07509229 — 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients · Phase 1, PHASE2 · not yet recruiting
NCT07405723 — Arm Position and Blood Pressure Measurement Accuracy During Pregnancy · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01991301 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheba Medical Center
Last refreshed: 1 December 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01991301.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing